Longeveron, Inc. (LGVN)
6.65
-0.15
(-2.21%)
USD |
NASDAQ |
Aug 28, 12:02
Longeveron Debt to Equity Ratio : 0.0559 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0559 |
| March 31, 2026 | 0.0467 |
| December 31, 2025 | 0.1452 |
| September 30, 2025 | 0.0986 |
| June 30, 2025 | 0.0901 |
| March 31, 2025 | 0.0755 |
| December 31, 2024 | 0.0661 |
| September 30, 2024 | 0.0624 |
| June 30, 2024 | 0.1172 |
| March 31, 2024 | 0.6235 |
| December 31, 2023 | 0.2983 |
| September 30, 2023 | 0.3246 |
| June 30, 2023 | 0.2047 |
| Date | Value |
|---|---|
| March 31, 2023 | 0.1502 |
| December 31, 2022 | 0.1264 |
| September 30, 2022 | 0.1109 |
| June 30, 2022 | 0.0976 |
| March 31, 2022 | 0.0875 |
| December 31, 2021 | 0.0837 |
| September 30, 2021 | 0.1525 |
| June 30, 2021 | 0.1435 |
| March 31, 2021 | 0.139 |
| December 31, 2020 | 2.116 |
| September 30, 2020 | |
| December 31, 2019 | 0.931 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 15.49M |
| Total Liabilities (Quarterly) | 5.085M |
| Shareholders Equity (Quarterly) | 10.40M |
| Current Ratio | 2.629 |
| Net Debt Paydown Yield | 0.64% |